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We have conducted proteome-wide analysis of fresh surgery specimens derived from breast cancer
patients, using an approach that integrates size-based intact protein fractionation, nanoscale liquid
separation of peptides, electrospray ion trap mass spectrometry, and bioinformatics. Through this
approach, we have acquired a large amount of peptide fragmentation spectra from size-resolved
fractions of the proteomes of several breast tumors, tissue peripheral to the tumor, and samples from
patients undergoing noncancer surgery. Label-free quantitation was used to generate protein abundance
maps for each proteome and perform comparative analyses. The mass spectrometry data revealed
distinct qualitative and quantitative patterns distinguishing the tumors from healthy tissue as well as
differences between metastatic and non-metastatic human breast cancers including many established
and potential novel candidate protein biomarkers. Selected proteins were evaluated by Western blotting
using tumors grouped according to histological grade, size, and receptor expression but differing in
nodal status. Immunohistochemical analysis of a wide panel of breast tumors was conducted to assess
expression in different types of breast cancers and the cellular distribution of the candidate proteins.
These experiments provided further insights and an independent validation of the data obtained by
mass spectrometry and revealed the potential of this approach for establishing multimodal markers
for early metastasis, therapy outcomes, prognosis, and diagnosis in the future.
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Introduction
Breast cancer accounts for 15% of all cancers diagnosed
and for 30% of all female cancers in the U.K. (http://info.
cancerresearchuk.org/cancerstats/incidence/commoncan-
cers/, July 2006). Each year more than 42 000 people in the
U.K. are diagnosed with the disease (99% of whom are women),
affecting one in nine women throughout the course of their
lifetime (http://info.cancerresearchuk.org/cancerstats/incidence/
females/?a)5441, July 2006) . In the EU, breast cancer is now
the second most commonly diagnosed cancer after bowel
cancer, and is the most common cause of female deaths from
cancer resulting in around 91 000 deaths per year (http://
info.cancerresearchuk.org/cancerstats/geographic/cancerineu/
incidenceandmortality/?a)5441, July 2006). Furthermore, the
incidence of breast cancer has continued to rise in economi-
cally developed countries such as the U.K. for many years,
placing an ever increasing burden upon public health services.
While research has succeeded in highlighting several risk factors
associated with breast cancer, many of the underlying causes
remain largely unknown. Better markers are needed for diag-
nosis, prognosis, and optimization of therapy. Research into
biomarkers using cell lines, human serum, and animal models
has so far resulted in limited success due to the specificities of
tumor biology. Proteomics is one of the new technologies
promising to deliver breakthroughs into cancer biomarkers.20It
should be especially efficient when applied directly to fresh
specimens derived from human tumors. Its ability to grasp the
qualitative and quantitative complexity of the proteome should
allow the development of cancer biomarkers of a novel
typesones that are based on the expression patterns of
multitude of proteins as opposed to single protein abundance.
So far proteomics has been mostly used for the profiling of
plasma and serum. It is tempting to use these readily
obtainable materials, but a decade of serum and plasma
proteomic investigations has shown that their proteomes are
too complex to define using approaches relying on total
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protein identification by mass spectrometry. It is likely that
the most useful molecules in unprocessed plasma and serum
are present at concentrations below the detection limit of
today’s mass spectrometers. Fractionation and affinity en-
richment can help, but they lead to an exponential increase
of the number of samples to be analyzed, rendering the
project unpractical. One alternative strategy is to look at the
tumors themselves and identify the proteome patterns that
distinguish them from healthy tissue or pathological phe-
notypes. If prospective markers overexpressed in tumor
tissue are established, these can be assayed in serum and
plasma using much more sensitive methods based on signal
amplification such as Western blotting, ELISA, and antibody
microarrays. The aim of this study was to explore the strategy
of comparing the protein profiles of freshly collected breast
cancer tumors and healthy tissue by combining established
analytical methods such as 1D SDS-PAGE and low-flow
electrospray ionization mass spectrometry supported by a
suit of recently developed bioinformatics tools. This allows
unattended analysis and integration of large-scale peptide
fragmentation data sets. Validation experiments employing
Western blotting and immunohistochemistry analyses of
selected proteins showed that this approach has the potential
to provide a powerful discovery platform in breast cancer
biomarker and drug development research.
Figure 1. Overview of the size-resolved differential profiling analysis of breast cancer specimens. The proteins of tumor and matching
periphery tissue samples were separated by SDS-PAGE into 10 fractions and digested, and the resulting peptides were analyzed
by nanoscale LC/MS/MS. Peptide fragmentation spectra were written into mzXML files and uploaded into the computational pipeline
(CPAS) for analysis. Protein hit lists were filtered with ProteinProphet at 0.95 protein probability and exported to MS Excel files.
The freeware program Hierarchical Clustering Explorer was used to produce the two-column heat map on the right showing
protein abundances as estimated by spectral counting. The most abundant proteins are bright red, the least abundant, bright
green.
Figure 2. MS/MS spectrum of the tryptic peptide SLEDLQDEYDFK from STAT1 detected in the 100–110 kDa fraction of the proteome
of one of the breast cancer tumor samples. Fragment assignments are shown in the table on the right-hand side by dark gray shading.
The spectrum was acquired in a 150 min nano-LC/MS/MS experiment as described under Experimental Procedures. Fragment
assignment, protein identification, and all statistical evaluations were performed automatically by the CPAS suite using X! Tandem
and the PeptideProphet tool from Trans-proteomic Pipeline. B and Y fragment ion series are indicated above the corresponding ion
peak in the spectrum.
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Experimental Procedures
Reagents. All chemicals, unless indicated otherwise in the
text, were from Sigma-Aldrich. The highest available grades
were used throughout the study. The primary antibodies were
purchased from Abcam and Santa Cruz Biotechnology.
Fresh Tissue Collection. All tissue was collected under LREC
and NHS Trust approval. All patients gave their informed
consent for the use of their tissue, collected as part of routine
treatment, in biochemical research. Surgical tissue was im-
mediately placed on ice in the operating theater to ensure that
the status of the tissue is as close as possible to its physiological
and biochemical status within the human body. The tissue was
assessed and cut by the pathologist on ice before being divided
up with a proportion of the tissue snap-frozen in liquid nitrogen
and the remainder fixed in formalin with the shortest possible
delay. Any tissue that was X-rayed or kept off ice was not used
in this study. Breast tissue peripheral to the cancer (clinically
normal) and normal breast tissue from patients undergoing
noncancer breast surgery were collected and processed as
described above.
Tumor Selection. For mass spectrometry analysis, tumors
were compared directly with corresponding clinically normal
Table 1. Proteins Found To Be Strongly Overexpressed in Breast Tumors Compared to Corresponding Peripheral Tissue Samples
(n ) 2) and Healthy Mammary Gland Tissue Samples (n ) 2)a
UniProt accession protein name protein function slice (kDa)
P35579 Myosin-9 Motility >150
Q5HY53 Filamin A Actin binding, filament branching >150
Q7Z351 Hypothetical protein Antigen presentation >150
Q9Y940 Talin-1 Attachment of the Actin cytoskeleton to the plasma membrane >150
P46940 IQGAP1 Binds to activated CDC42 GAP but does not stimulate its
GTPase activity
>150
O14746 Telomerase reverse transcriptase Telomerase component 120–150
P01024 Complement C3 Activation of the complement system, inflamation 120–150
P18206 Vinculin Cell adhesion, attachment of the Actin cytoskeleton to the
plasma membrane
120–150
Q9Y4L1 150 kDa oxygen-regulated protein Suppressor of hypoxia induced apoptosis, protein folding 120–150
Q13813 Spectrin alpha Calcium-dependent movement of the cytoskeleton 120–150
Q8NF91 Nesprin Nuclear envelop protein, Actin binding 120–150
Q9BSJ8 Fam62a Membrane bound, contains C2 domains 120–150
P12814 Alpha actinin Actin binding and bunling of F-Actin 100–110
P55072 TER ATPase Transitional ER ATPase 100–110
P42224 STAT1 Signal transduction and activation of transcription 100–110
P20929 Nebulin Binds to F-Actin and titin 100–110
P11021 GRP 78 Protein folding and complex assembly 70–100
P13667 Protein disulfide-isomerase A4 -S-S- rearrangement 70–100
P26038 Moesin Connection of the cytoskeleton to the plasma membrane 70–100
P04220 Ig mu heavy chain Antigen binding 70–100
P06396 Gelsolin Actin deploymerization 70–100
P02787 Transferrin Iron binding and transport 60–70
P13796 L-Plastin Actin binding 60–70, 50–60
P19971 Thymidine phosphorylase Catalyzes reversible phosphorolysis of thymidine.
Promotes angiogenesis
50–60
P25705 ATP synthase alpha ATP synthesis 50–60
P06576 ATP synthase beta ATP synthesis 50–60
P30101 Protein disulfide isomerase A3 -S-S- rearrangement 50–60
Q15084 Protein disulfide isomerase A6 -S-S- rearrangement 50–60
P41219 Peripherin Intermediate filaments 50–60
P00738 Haptoglobin precursor Binds free hemoglobin 50–60
P78418 PEG3 protein Zing finger protein, parentally imprinted 50–60
P01891 MHC class I antigen A-68 Antigen presentation 50–60
P10316 MHC class I antigen A-69 Antigen presentation 50–60
multiple Immunoglobulin proteins Antigen binding 50–60
Q562X4 Actin like protein Protein binding 40–50
P13645 Keratin 10 Intermediate filaments 40–50
Q6NSB4 HP protein Binds free hemoglobin 30–50
Q59HH1 Zinc finger protein 278 DNA binding 20–30
O00299 NCC27 Chloride ion channel 20–30
P67936 Tropomyosin 4 Actin binding 20–30
P52907 CapZ apha 1 Actin capping 20–30
P05388 L10E Acidic ribosomal protein 20–30
P25786 Proteasome subunit alpha type 1 Protein turnover 20–30
Q7Z4W7 Rab like protein GTP binding, protein transport, signal transduction 20–30
Q6JZS5 Nanog protein Transcription factor, regulation of gene expression 20–30
P08572 Collagen alpha- 2(IV) chain Component of the extracellular matrix 20–30
P55042 RAD protein GTP binding, signal transduction 20–30
Q9BWA9 HNRPA2B1 protein RNA binding 20–30
Q69YU5 Hypothetical protein DKFZp547P055 Unknown 10–20
Q06830 Peroxiredoxin-1 Redox regulation of the cell 10–20
P30041 Peroxiredoxin-6 Redox regulation of the cell 10–20
P62258 14–3–3 protein epsilon Signal transduction 10–20
P02766 Transthyretin Thyroid hormone binding 10–20
Q502W4 IGKC protein Antigen presentation 10–20
a Two ER-/PgR-, node positive tumors were compared with their clinically normal periphery and with 2 normal breast tissue samples. Only proteins
detected with more than 2 high-scoring peptides in both tumor samples but not detected in the peripheral or normal samples are included in the data set.
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peripheral tissue, or were matched for size, type, histological
grade, and receptor status (estrogen (ER), progesterone (PgR),
and ErbB 2 (HER2) receptors) differing only in their nodal
status. One group of tumors had nodes positive for cancer cells
and the other was negative. This was to allow comparison of
tumors that have displayed the ability to move from the
primary site with those that have not to identify proteins that
are related to the early stages of metastasis.
For initial validation of proteins selected from MS/MS data,
a wide range of tumor samples were selected to assess
consistency of expression in all types of breast cancers. For
further analysis of proteins showing interesting trends, further
tumor samples phenotypically matched but differing in nodal
metastasis were chosen.
All tumor samples were identified so that the pathological
findings could also be matched with prospective and retro-
spective clinical data from patient records and subsequent
research findings.
Protein Sample Preparation. Proteins were extracted by
mechanically homogenizing the samples in sample buffer
containing 2% SDS, 50 mM Tris-HCl, pH 6.8, and protease and
phosphatase inhibitors. Tissue homogenates were centrifuged
at 16 000g for 15 min, and the clear supernatant was aliquoted
and stored at -80 °C until needed for analysis. Prior to
electrophoresis, the proteins were chloroform/methanol-
precipitated and resuspended in the same sample buffer.
Membrane Protein Enrichment. Membrane proteins were
enriched from tumor tissue using the Mem-PER eukaryotic
membrane protein extraction kit from Pierce Biotechnology.
Gel Electrophoresis Prior to Mass Spectrometry. SDS-PAGE
according to Laemmli12 was performed with reduced samples
using precast gradient minigels (Invitrogen) and standard
protocols for separation and staining. Gels were stained with
ethanol-based Coomassie Blue G-250 stain.
Protein Digestion and Preparation of Samples for Mass
Spectrometry. Gel slices were subjected to in-gel digestion as
previously described by Metodiev et al.18 with some modifica-
tions to ensure better recovery of the peptides. Gel slices were
destained by several changes of solution containing 100 mM
NH4HCO3 and 50% acetonitrile and dehydrated in 100%
acetonitrile before drying in a vacuum concentrator. Gel slices
were reduced for 1 h in 12 mM DTT at 37 °C and subsequently
alkylated with 55 mM iodacetamide in the dark. Gel slices were
dehydrated again, dried, and rehydrated in trypsin solution at
enzyme concentration of 20 µg/mL. Promega trypsin of MS
grade quality was used throughout the experiments. After 18 h
of incubation at 37 °C, the peptides were extracted and the
samples evaporated to dryness. Evaporated peptide samples
were stored at -80 °C until needed for analysis.
Nanoscale LC/MS/MS Analysis. The analysis of protein
digests was performed using Ultimate II nano-LC (Dionex)
coupled to Esquire HCT ion trap mass spectrometer (Bruker
Daltonics) via online nano electrospray ion source. Sample
introduction was via the micro autosampler Famos (Dionex).
The peptides were separated by a biphasic 150 min binary
gradient as follows: 10 min at 2% solvent B, followed by 90 min
linear gradient to 30% B, followed by 40 min linear gradient to
50% B, followed by a wash for 5 min in 90 B. The flow was
Table 2. Candidate Membrane Protein Markers for Early Metastatic Eventsa
UniProt accession protein name protein function spectral count
Q6PYX1 Hepatitis B virus receptor binding protein Receptor activity 68
P13796 L-Plastin Motility 16
Q6N096 Unknown protein Protein binding 15
P08133 Annexin 6 Ca binding 14
Q13965 CD36 antigen Receptor 12
Q99536 VAT1 Membrane protein, quinone oxidoreductase 11
P12111 Collagen alpha-3(VI) Cell binding 11
P26038 Moesin Connects cytoskeleton to membrane 10
Q16853 Membrane copper amine oxidase Cell adhesion 9
P28331 NADH-ubiquinone oxidoreductase 75 kDa subunit NADH oxidation 8
Q01518 CAP1, Adebylyl cyclase-associated protein 1 Filament dynamics 7
P07339 Cathepsin D Protease, involved in breast cancer pathogenesis 6
P07384 Calpain 1 Protease, signaling 6
Q16891 Mitofilin Cell proliferation inducing gene, mitochondrial
inner membrane protein
6
Q562R1 Actin-like protein Cytoskelleton 5
P62873 G beta protein Signal transduction 5
P00505 Transaminase A Fatty acid metabolism 5
Q7L4N5 Transmembrane protein 43 Unknown, multipass membrane protein 5
P49748 VLCAD Fatty acid oxidation 5
P04217 Alpha 1B glycoprotein Unknown, secreted protein 5
Q5TBT2 Fistronin Actin binding 5
Q53HS5 Integrin beta 2 Cell adhesion 5
Q96QE2 Proton myo-inositol cotransporter Multipass membrane protein, transporter 4
O75083 AIP1 Cytoskeleton organization 4
Q9Y490 Talin1 Cytoskeleton to plasma membrane contacts 4
O00299 CLC1 Chloride channel 4
Q16647 Prostacyclin synthase Prostaglandin metabolism 3
Q2YD73 Coronin 1A Cytoskeleton dynamics, phagocytosis 3
Q5VZ18 SHE SH2 domain adapter protein 3
a Proteins identified with more than 2 peptides in the membrane fraction of pooled node negative cancer samples (n ) 3) but not in the node-positive
sample pool. The node-positive and node-negative tumors were matched for all other phenotypic parameters.
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kept at 250–300 nL/min. The column used was Pepmap 75, a
75 µm i.d., 150 mm long reverse-phase column packed with 3
µm C18 silica particles (Dionex). The mass spectrometer was
controlled by the manufacturer control software and operated
in a data-dependent acquisition mode with the following
settings: the threshold for detection was 25 000; the number
of precursors was set to 3; the number of scans to be averaged
was set to 3; the intelligent ion control (ICC) was set to 200 000.
A mixed scan mode was used to select only multiply charged
ions for MS/MS analysis. Under this mode, the instrument
performs a survey scan at 8100 unit/s, which allows determi-
nation of charge states up to 3. Next, the 3 most intense
multiply charged precursors are isolated and fragmented, and
the fragments’ m/z is determined using an ultra fast scan at
26 000 units/s. A dynamic exclusion was used to exclude
analyzed precursors for 1 min after their second isolation by
the instrument.
Bioinformatics and Data Analysis. MS/MS data were ana-
lyzed by an integrated analytical pipeline consisting of 2
computer workstations and a dedicated server using CPAS
(Computational Proteomics Analysis System) and X! Tandem
as search engine.16 The raw MS data files were converted to
mzXML files21 using the compassXport program from Bruker
Daltonics. The mzXML files were loaded into an automatic data
analysis pipeline running under the experimental CPAS
environment.3,22 The CPAS suite version 1.4 was installed on a
dual Xeon 64 bit processor server operating under the 64 bit
SUSE 9.2 version of Linux and configured with Postgres 8.0.6
as a database and Jakarta Tomcat as a servlet container and
web server. Postrgres and Tomcat were built from source prior
to installation. The Transproteomic Pipeline (TPP) from the
Seattle Institute of Systems Biology was integrated into the
CPAS environment to provide statistical analysis of the protein
identification data via its Peptide Prophet and Protein Prophet
tools.11 Uniprot and the International Protein Index (IPI)
databases were used to perform protein identification.
Gene Ontology Term Enrichment Analysis. Protein identi-
fied to be significantly overexpressed in the breast tumor tissue
were analyzed using the GOLEM program24 to identify biologi-
cal process and molecular function categories enriched in the
data set. The program uses the following formula for hyper-




n (Mj )(N-Mn - j )
(Nn )
where N is the total number of genes in the Human annotation
file, M is the number of annotated genes in a given GO term,
and n is the number of genes in the input data set. The p-value
gives the probability that k or more genes from the data set
will be assigned to a given GO term. Bonferoni correction for
multiple hypotheses2 was used as implemented in the GOLEM
algorithm.
Quantitative Analysis. Relative abundance of the identified
proteins was determined using the spectral counting method
as described previously.15Comparison of protein profiles was
achieved automatically by the “Compare Proteins” function of
the MS2 module of CPAS. The results from the comparisons
were exported to MS Excel files. The freeware program HCE
(Hierarchical Clustering Explorer)25 was used to integrate and
visualize the protein abundance maps based on the quantita-
tion by spectral counting.
Western Blotting Analysis. Breast cancer, tissue proximal
to the tumor, and normal breast tissue were cut into small
pieces while the tissue remained on dry ice and then homog-
enized in ice-cold lysis buffer containing 50 Mm NaCl, 1 mM
EDTA, 10 Mm Tris-HCL, pH7.4, 1% Igepal, 1 mM EGTA, 1 mM
Table 3. Candidate Membrane Protein Markers for Early Metastasisa
UniProt accession protein name protein function spectral count
Q12907 VIP36 Secretion 8
Q08431 Lactadherin Specific ligand for the alpha-v/beta-3 and
alpha-v/beta-5 receptors
8
P08729 Cytokeratin 7 Cytoskeletal protein 8
Q9HAV0 GNB4 Signal transduction 6
Q6N090 Putative protein Unknown 6
P20774 T Mimecan Induces bone formation in conjunction with
TGF-beta-1 or TGF-beta-2
:O60283 KIAA0534 protein Sugar binding, development 5
P29043 Serpin-H1 Collagen binding protein, chaperon 5
Q07960 Rho GAP 1 Signal transduction 5
Q00325 Phosphate carrier protein Ion transport 4
Q96AG4 Leucine-rich repeat-containing protein 59 Leucine rich membrane protein 4
Q01955 Collagen alpha-3(IV) chain Structural protein 4
P59091 Unknown protein Unknown 3
P43307 TRAP-alpha Regulates Ca fluxes 3
P63244 Guanine nucleotide-binding protein subunit
beta-2-like 1
Signal transduction 3
Q659E8 Putative protein Oxidoreductase activity 3
Q8WZ27 Putative protein Unknown 3
Q9NQC3 Nogo protein Neurite outgrowth inhibitor 3
Q9HCK4 Roundabout homologue 2 Receptor for SLIT2 3
Q4VX75 Ezrin Probably involved in connections of major cytoskeletal
structures to the plasma membrane.
3
Q8TF66 Leucine-rich repeat-containing protein 15 Membrane protein 3
Q96SD1 Cytokeratin 6A Cytoskeletal protein 3
a Proteins exclusively identified with more than 2 peptides in the membrane fraction of pooled node-positive cancer samples (n ) 3) but not in the
node-negative sample pool. The node-positive and node-negative tumors were matched for all other phenotypic parameters.
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PMSF, 1 µg/mL aprotinin, 1µg/mL leupeptin, 1 mM Na4P2O7,
and 25 mM NaF. Lysates were centrifuged to remove any fatty
deposit, solid, and DNA/RNA contaminants. The protein
concentration was determined by the Bio-Rad Detergent-
Compatible protein assay.
Protein Separation by SDS Gel Electrophoresis and
Western Blot Analysis. Protein samples were boiled in reducing
sample buffer for 5 min. Proteins were resolved on acrylamide
SDS gels and transferred to polyvinylidine difluoride mem-
branes (Millipore).
Membranes were blocked with 3% (w/v) nonfat dried milk
in PBS and incubated with the appropriate primary antibody
at room temperature for 1 h. Following four washes in PBS-
Tween 20, membranes were probed with the appropriate IR-
conjugated secondary antibody (LI-COR Biosciences) at 1/2000
for a further hour at room temperature. Proteins were visualized
using the ODYSSEY Infrared Imaging System (LI-COR Bio-
sciences).
Proteins of interest were normalized against acitn expression
and densitometric analysis was conducted using ODYSSEY
software.
Immunohistochemistry. Immunohistochemistry was per-
formed on a panel of paraffin-embedded sections of a range
of breast tumor phenotypes, from tissue collected on ice as
above. For antigen detection, deparaffinized sections were
treated in a microwave for 20 min at 900 W in 10 Mm citrate
buffer (pH 6.10). Endogenous peroxidase activity was inhibited
with a mixture of H2O2/methanol (12 mL of H2O2 in 400 mL
Figure 3. Identification of enriched Gene Ontology terms in the breast cancer data set from Table 1. Gene Ontology (GO) assignments
for the identified proteins were from www.geneontology.org. The distribution of proteins across different molecular function and
biological process types is represented by pairs of percentage bars. Open bars denote general Human proteome data, and gray bars
are for proteins identified as significantly overrexpressed in breast carcinomas as compared to the matched peripheral tissue. GO
categories enriched in the breast cancer data set were identified by calculating p-values using the hypergeometric distribution and the
GOLEM program as described in Experimental Procedures. A p-value cutoff of 0.05 was used to generate the graphs; only GO terms
with p-values lower than the cutoff are shown. The complete output of the GOLEM analysis is available in the Supporting Information.
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of methanol) for 12 min. Primary antibodies incubation was
carried out for an hour at room temperature. Secondary
biotinylated conjugated antibodies and tertiary ABC complexes
(VectorLab) incubations were carried out for 30 min at room
temperature. Detection of antibodies was performed using
diamino-benzidine (DAB) as a chromogen (ImmPACT, Vector
laboratories). Cell nuclei were counterstained with heamatoxy-
lin. Slides were analyzed on an Olympus BX41 and images
captured using image analysis software provided by Olympus.
Results and Discussion
Mass Spectrometry. In this study, we have analyzed fresh
tumor, paired peripheral tissue, and normal tissue from the
human mammary gland. We have also analyzed the membrane
proteomes of pooled samples of 3 metastatic and 3 nonmeta-
static breast cancers that were matched for all other phenotypic
parameters. Each protein sample to be analyzed was separated
into 10 size-resolved protein fractions by slicing the SDS-PAGE
lanes into segments of 10–20 kDa. The slices were subjected
to in-gel digestion and subsequent analysis by nano-LC/MS/
MS. On average, 4–5000 searchable MS/MS spectra were
recorded during the course of each individual LC/MS/MS run.
The final raw data set consisted of more than 500 000 peptide
fragmentation spectra. The raw data files were converted to
mzXML and uploaded into CPAS for analysis. Figure 1 il-
lustrates the experiment and the nature of the obtained results.
For each analyzed sample, a heat map of protein abundances
is generated. Clustering algorithms are then used to identify
the proteins that are significantly overexpressed in tumor
tissues compared to the periphery and the normal tissue.
Similar heat maps can be used to compare different tumors or
to compare tumors with cells grown in culture.
1. Size-Resolved Differential Profiling of Tumor versus
Clinically Normal Peripheral Tissue Proteomes: Methodo-
logical Potential for the Detection of Biomarkers of Breast
Cancer. More than 2000 proteins were positively identified
based on ProteinProphet probability of 0.95 and above. About
half of these proteins were identified with 2 or more peptides.
To ensure that candidate biomarker status is not assigned to
occasional false-positive hits, we used an additional stringent
filter: all proteins discussed in this study were identified by at
least 2 peptides with PeptideProphet scores higher than 0.95
and CPAS Expect values lower than 0.01. A representative MS/
MS spectrum demonstrating the quality of the acquired data
and fragment assignments is shown in Figure 2. The spectrum
is matched to a peptide derived from the transcription factor
STAT1. STAT1 was identified with multiple high-score peptides
in the 70–100 kDa fraction of tumor sample but was not
detected in the periphery and normal samples. STAT1 is found
in various tumors and human cancer cell lines; however, there
is limited information on its role in breast cancer.26 Lists of
identified proteins with corresponding high-score peptides
from 1 cancer and matched periphery are available in the
Supporting Information.
The most abundant proteins in some of the fractions gave
more than 200 spectral counts. Cytokeratin, albumin,and
transferrin are three examples of very abundant proteins
detected in the 60–70 kDa fractions of all analyzed samples
from breast tissue.
Table 1 lists the proteins that were found to be significantly
overexpressed in tumor tissue based on the analysis of 2 tumors
and the corresponding peripheral tissue samples. Among these
are several proteins potentially implicated in breast cancer such
as L-plastin, STAT1, haptoglobin, and thymidine phosphor-
ylase.5,7,14,29 Proteins that are known to be involved in the
regulation of the cytoskeleton are also prominent in this list.
These include L-plastin, moesin, gelsolin, and talin. Chaperones
such as GRP 78 and several protein disulfide isomerases were
also found to be much more abundant in tumors than in the
peripheral tissue and the healthy tissue.
Several proteins involved in signal transduction were de-
tected in the tumor sample but not in the peripheral or healthy
tissue. Such are IQGAP1, a 14–3–3 protein, and a Rab-like
GTPase (Table 1). A 150 kDa oxygen regulated protein, a known
cancer marker, was also detected only in the tumor tissue but
not in the periphery or normal mammary gland tissue.
Figure 4. Stat1 and Nanog expression in carcinomas and normal breast tissue. Whole cell lysates from three individual cases of (A)
ER+/PgR+ node positive (C193, C198, C194) and node negative (C148, C143, C2) Invasive Ductal Carcinomas (IDC [+/- DCIS]) and (B)
ER-/PgR- node positive (C106, C173, C136) and node negative (C170, C167, C169) Invasive Ductal Carcinomas (IDC [+/- DCIS]) and
tissue from two individual breast reduction mammoplasties (N8, N9) were subjected to SDS-PAGE followed by Western blot analysis.
Total Stat1 and Nanog expression was detected using anti-Stat1 and anti-Nanog antibodies, respectively. Equal loading of lanes was
maintained by performing a total protein assay and is confirmed by Western blot analysis using an anti-Actin antibody.
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A very interesting result is the identification of the home-
odomain protein nanog. This protein is expressed in embryonic
stem cells and was recently shown to be necessary and
sufficient for their pluripotency.27
2. Membrane Protein Profiles of Tumors That Have
Metastasized to the Lymph Nodes versus Tumors That
Have Not Metastasized to the Lymph Nodes: Methodo-
logical Potential for Detection of Biomarkers of Early
Metastasis. A pool of the membrane proteomes of 3 cancers
that have metastasised to the lymph nodes were compared to
a pool of the membrane proteomes of 3 nonmetastatic cancers.
Membrane proteins were used to increase the possibility of
discovering proteins that are involved in signal transduction/
adhesion/migration, that would be easily accessible as biom-
arkers and to decrease the noise from the millions of distinct
proteins that are in a cell at anyone time. Table 2 lists 29
proteins detected only in the membrane fraction of the
nonmetastatic cancer sample pool. L-Plastin, although not an
integral membrane protein, is again identified as a protein
specifically overexpressed in the nonmetastatic tumor sample.
This is not consistent with validation experiments where
L-plastin is seen in metatstatic tumors by Western blot and IHC.
However, this may be an interesting observation suggesting that
L-plastin has a tighter association with the membrane in
nonmetastatic tumors, indicating a spatially regulated role in
metastasis. Table 3 lists 22 proteins that were detected in the
metastatic tumor sample but not in the nonmetastatic sample.
An intriguing example of a candidate marker for invasiveness
is lactadherin, a protein that promotes cancer cell adhesion
via integrins.28 We detected this protein with 5 peptides in the
membrane fraction of the metastatic cancer sample pool but
did not detect it in the nonmetastatic cancer sample pool. The
result suggests that lactadherin is much more abundant in
metastatic tumors and could potentially be used as a marker
for invasiveness.
3. Distribution of the Identified Candidate Markers
Across Molecular Function and Biological Process Classes:
A Comparison with the Human Proteome. Figure 3 presents
a statistical assessment of the obtained results based on a
comparison with the Human proteome. Gene ontology (GO)
was used to classify the identified candidate marker proteins
by molecular function and biological process. The top panel
shows the enriched biological process categories. Most of the
strongly enriched terms associate with regulation of the cy-
toskeleton, motility, and organelle biogenesis and localization.
The bottom panel shows the results of a similar analysis but
based on the GO term molecular function. Strongly enriched
functions are Actin binding, peroxiredoxin activity, calmodulin
Figure 5. L-Plastin protein expression in breast carcinomas. (A) Expression of L-plastin in ER+/PgR+ receptor carcinomas. Upper panel,
Western blot analysis; middle panel, densitometry (n ) 3 individual cases per group); lower panel, IHC (original magnification ×40) (a)
negative control, (b) normal tissue (arrows indicate myoepithelial cells), (c) malignant cells (arrows indicate nonstained malignant
cells), and (d) malignant tissue (arrows indicate positive staining of myoepithelial cells). (B) Expression of L-plastin in ER-/PgR- receptor
carcinomas. Upper panel, Western blot analysis; middle panel, densitometry; lower panel, IHC, original magnification ×40, (e) negative
control, (f) lymphocytes (indicated by arrows), (g) cytoplasmic and nuclear staining, (h) myoepithelial staining.
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binding, and intramolecular oxidoreductase activity. A table
with the complete set of results from the GO analysis is
available in the Supporting Information.
In summary, two groups of proteins are strongly over
presented in the breast cancer data set, the proteins involved
in response to stress and the proteins involved in cellular
motility and regulation of the cytoskeleton. It is worth noting
that these two groups exemplify functions that are critical for
the survival of the tumor cells and for their invasiveness and
metastasis.
Validation Experiments. To check the validity of the results
obtained by mass spectrometry, we conducted Western blotting
and immunohistochemical staining experiments using anti-
bodies specific for several of the proteins detected only in the
tumors but not in healthy or peripheral tissue samples.
L-Plastin, thymidine phosphorylase (TP), STAT1, CLC1, and
Nanog were chosen for analysis due to relevance considerations
and availability of good antibodies.
STAT1 and Nanog showed diverse patterns of expression
with no apparent correlation with nodal status or histological
grade (Figure 4). Shen-chen et al.26 also found no correlation
Figure 6. Thymidine phopsphorylase protein expression in breast carcinomas. (A) Expression of thymidine phosphorylase in ER+/
PgR+ receptor carcinomas. Upper panel, Western blot analysis; lower panel, densiometric analysis (n ) 3 individual cases per group).
(B) Expression of thymidine phopsphorylase in ER-/PgR- receptor carcinomas. Upper panel, Western blot analysis; lower panel,
densiometric analysis (n ) 3 individual cases per group). (C) IHC showing cellular distribution and intensity of thymidine phosphorylase
in tumors of differing grade, original magnification ×40, (a) negative control, (b) normal tissue showing expression in epithelial and
macrophage cells, (c) a representative grade 2 tumor (IDC +/-DCIS ER+/PgR+) showing expression in malignant cells, (d) a representative
grade 3 tumor (IDC +/-DCIS ER+/PgR+) showing no expression in the malignant cells and some lymphocytic expression.
Figure 7. CLC1 analysis by Western blotting in membrane
fractions of metastatic and nonmetastatic cancers. Membrane
proteins were enriched as described in Experimental Procedures.
CLC1 was detected with anti-CLC1 mouse monoclonal primary
antibody and fluorescent antimouse secondary antibody. (Bar
graph) Quantitative analysis of CLC1 abundance in node-positive
membrane protein isolates and node-negative membrane protein
isolates. Fluorescence intensity was determined using the Odys-
sey software. Values are mean of 4 individual node-positive
cancers and 4 individual node-negative cancer samples. (Inset)
A representative Western blot analysis of pooled node-positive
(n ) 3) and node-negative (n ) 3) membrane protein samples.
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of STAT1 expression with age, receptor status, grade, lymph
node metastasis, and overall survival rate. Nanog is a transcrip-
tion factor that plays a key role in self-renewal and mainte-
nance of pluripotency in human embryonic stem cells. Links
to breast cancer include the expression of NANOGP8 in cancer
cell lines and cancer tissues31 and in breast carcinomas.
L-Plastin was significantly more abundant in all cancers
tested (ILC and IDC II, data not shown) compared to normal
samples. However, no significant difference between metastatic
and nonmetastatic tissue was seen in Western blots (Figure 5A).
L-Plastin is a protein specific for blood cells but is also known
to be expressed in some breast cancers cell lines. It has been
detected with antibodies in many solid tumors including breast
tumors.13 Although it is a protein already implicated in breast
cancer, it could be a useful validation experiment to study its
expression in our panel of breast cancer specimens. In par-
ticular, we were interested to determine to what extent detec-
tion of L-plastin in cancer samples was due to leukocyte
infiltration rather than endogenous expression by the malig-
nant cells. Immunohistochemitry experiments (Figure 5B)
revealed that the majority of L-plastin expression was seen in
infiltrating leukocytes and benign myoepithelia, which high-
lights the problem of interpretation of results from hetreog-
enous tissue. However, we found that ER/PgR-negative, node-
negative IDC breast tumors did express L-plastin in the
malignant cells. This result is similar to the data reported by
Lapillone et al.13 with the exception that we do not detect
L-plastin in normal epithelial tissue by immunohystochemical
staining.
Thymidine phosphorylase was specifically detected in all
types of breast cancer tissue (ILC and IDC II, data not shown)
but not in normal tissue. The protein showed a trend (although
not highly significant with this sample size) of increased
expression in node-negative ER-/PgR- tumors compared to
node-positive tumors with the same receptor status (Figure 6A).
Immunohistochemistry experiments (Figure 6 B) revealed that
the protein was expressed in the nucleus and the cytoplasm
of the malignant cells. There was also some stromal staining,
although this appeared to be fibrous and not cellular. Mac-
rophages also expressed thymidine phosphorylase. This protein
showed an interesting pattern of expression in malignant cells
that correlated with the grade of the tumor. Malignant cells in
lower grade tumors have abundant expression compared to
the malignant cells in the higher grade tumors. This may allude
to the potential of using thymidine phosphorylase as a prog-
nostic indicator. This is supported by the work of Ioachim et
al., who found that high levels of thymidine phosphorylase were
significantly associated with a favorable outcome.9 The valida-
tion data for these two proteins illustrate some of the advan-
tages and pitfalls of proteomic approaches to discovery. The
heterogeneity of the tissue can yield results that are irrelevant
to the malignant cells. However, with thorough post-MS
validation, interesting cell-specific patterns can be discovered
that correlate with related pathologies of breast cancer.
CLC1 was not detected by Western blotting in total tissue
lysates. However, as shown on Figure 7, CLC1 was consistently
found to be more abundant in the membrane fractions isolated
from nonmetastatic tumors compared to the membrane frac-
tions from metastatic tumors. This supports the data obtained
by mass spectrometry (Table 2) and suggests that early me-
tastasis may be associated with decreased expression of this
protein in the membranes of, as yet unspecified, cell types in
the heterogeneous tumor tissue.
Notes on Methodology. Proteomic technologies, including
bioinformatic analysis tools, have progressed to a level to allow
their application to solve clinical problems. It is now possible
to identify pathological components of a disease by large-scale
analysis of expressed proteins. Advances in protein biochem-
istry as well as robust established techniques allow validation,
monitoring, and functional analysis of discovered protein
candidates. Despite this, no protein identified by proteomics
has as yet made it to the clinic as a viable breast cancer
biomarker, suggesting that better fusion of the postgenomic
research methodology with clinical practice is needed. One of
the strengths of our approach is the synergy of clinical and
proteomic studies from the outset. The use of rigorously
collected human samples together with prior and follow-up
pathological/clinical and life-style data should reduce variability
due to sample origin, collection, and handling, and should
bring the discoveries obtained by proteomics a step closer to
the establishment of novel markers and drug target candidates.
A large variety of experimental strategies and approaches
based on mass spectrometry are now available for the needs
of cancer proteomics, each with its own strength and weak-
nesses (reviewed in refs 1 and 20). In this study, we have chosen
an approach that combines 1D-SDS-PAGE and nanoscale LC/
MS/MS. 1D-SDS-PAGE is very robust and reproducible tech-
nique and is by far the highest resolution protein separation
method. Nano-LC/MS has matured and is one of the most
powerful platforms for ultra sensitive analysis of peptides. In
this study, 1D-SDS-PAGE served as initial top-down fraction-
ation step prior to the LC/MS/MS analysis. The method is
equally appropriate for the separation of soluble and mem-
brane proteins, for highly acidic and basic proteins. It provides
information for the size of the separated proteins, which is
important in the subsequent analysis. In previous years, 1D-
SDS-PAGE was regarded as inferior to 2-DE, because of the
need to use peptide mass fingerprinting for the subsequent
identification of proteins. Peptide mass fingerprinting (PMF)
requires highly purified sample; hence, 1D-SDS-PAGE where
any given band can contain as many as 100 detectable proteins
was not the method of choice. 2-DE in combination with
MALDI-TOF and fingerprinting is still the predominant tech-
nology in many proteomics laboratories. Its inherent lack of
throughput is ameliorated to some extent by the use of robotic
spot pickers and automatic digestion and spotting stations, but
this cannot circumvent the low sensitivity and moreover the
lower reliability of protein identification associated with PMF.
Several alternatives to 2-DE/MALDI have been developed to
solve these problems. An example is the MuDPIT method
which does not include any separation of intact proteins.30
Although very powerful, this method has its own shortcomings;
since protein inference is based on peptides detected and
identified by MS/MS analysis of protease digests of unseparated
protein samples, all information about isoforms and splice
variants is lost in this analysis. There are also technical
problems accompanying the attempt to analyze many millions
of peptides in a single LC run. Ionization suppression, over-
loading of the system, and poor reproducibility are some of
the known problems.
In this study, 1D-SDS-PAGE was used to generate size-
resolved fractions of the proteomes of cancer, normal and
peripheral to cancer tissue samples. The proteins in these
fractions were digested and the generated peptides were
analyzed by a fully automatic system consisting of an autosam-
pler, nanoscale separation module, and a fast-scanning, high-
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capacity ion trap mass spectrometer. The tandemmass spectra
generated from each fraction were converted to mzXML files21
and uploaded automatically into a data analysis pipeline based
on open source tools such as CPAS4,22 and the Transproteomic
Pipeline.11 This experimental setup affords the identification
of as many as 2000 proteins in a single day. Several hundred
of these proteins are detected with multiple peptides and are
quantified automatically by the pipeline using the spectral
count method.15 The outcome of such an analysis is a set of
differential displays which reveal the patterns that distinguish
healthy from diseased specimens and can be used to establish
multimodal biomarkers and to discover drug target candidates.
Unlike other methods that have been applied to breast tumor
samples, such as SELDI for example,17 MS/MS delivers true
protein identities, and more importantly, the relative abun-
dance of these proteins can be estimated. Prefractionation by
SDS-PAGE is a very useful and reproducible way to decrease
sample complexity. As a top-down approach, it has the
advantage of preserving the information about protein isoforms
such as splice variants, unlike MuDPIT and other shot-gun
methods. It is worth noting also that in all analyzed samples
we detected large amounts of several serum proteins. Most
notably, these were albumin, transferin, and various immu-
noglobulins. This shows that the efficiency and potential of the
SDS-PAGE-LC/MS approach could be increased dramatically
by using an additional prefractionation step to deplete these
high-abundance proteins from the samples. We expect that
such depletion will increase the number of reliably quantifiable
proteins to 1000 and more.
An important feature of the approach implemented in this
study is the use of label-free quantitation. Although this method
is not as precise as stable isotope based methods such as ICAT,
ITRAQ, and IPCL,8,23,3 it is good enough to detect differences
in abundance as small as 30%.19 This is sufficient for the needs
of a typical biomarker discovery project. In fact, it might be
that it is sufficient to only stratify the identified proteins into
relatively broad abundance groups and then select for valida-
tion protein hits that are found in some of the high-abundance
group in tumors but are not detected at all or detected with
1–2 spectra in the control sample. Label-free quantitation has
an additional advantage over isotope-based techniques. It
allows an unlimited number of experiments to be cross
compared even when some of these experiments have been
performed long periods of time apart. This is essential as our
strategy is to continue to acquire data from tumors and control
tissue over a long period of time. At present, we have collected
over 200 different tumor specimens and matching periphery
tissue samples. The tumors are grouped according to their
phenotype, grade, size, ER/PgR status, HER2 expression, and
nodal status. We also have samples from patients that have
undergone primary chemotherapy showing differing responses,
for analysis of proteins involved in resistance to chemotherapy.
All these samples will give rise to a data set of many millions
of MS/MS spectra, and the use of label-free quantitation will
allow us to use a simple unbiased approach to compare the
abundance of all identified proteins across all samples and
proteome fractions.
Concluding Remarks
We have combined robust and mature analytical techniques
and advanced bioinformatics tools into an integrated research
platform for identification and validation of breast cancer
biomarkers using freshly collected, fully characterized human
breast tissue. With this approach, we have identified, quanti-
fied, and validated proteins from samples derived from different
types of tumor, tissue peripheral to the tumor, and normal
breast tissues. So far we have collected over 500 000 MS/MS
spectra from size-resolved proteomes from selected phenotypi-
cally matched tissue samples which led to identification of
established and novel breast cancer protein biomarker candi-
dates, demonstrating the utility and effectiveness of the ap-
proach. Selected proteins were studied by Western blotting and
immunohistochemistry techniques to validate the results ob-
tained by mass spectrometry. We are currently using this
platform to analyze a cohort of over 200 tumors and matching
periphery tissue samples for further validation and discovery
and to establish a growing tumor proteome database.
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